{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:13:54Z","timestamp":1791137634614,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,5,19]],"date-time":"2012-05-19T00:00:00Z","timestamp":1337385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s10549-012-2092-7","type":"journal-article","created":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T16:24:33Z","timestamp":1337358273000},"page":"561-567","source":"Crossref","is-referenced-by-count":53,"title":["Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer"],"prefix":"10.1007","volume":"134","author":[{"given":"Tobias J.","family":"Grob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Heilenk\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Geist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Paluchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Jaenicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Wilczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Choschzick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lebeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,19]]},"reference":[{"issue":"20","key":"2092_CR1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938\u20131948","journal-title":"N Engl J Med"},{"issue":"19","key":"2092_CR2","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djg050","volume":"95","author":"WD Foulkes","year":"2003","unstructured":"Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19):1482\u20131485","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"2092_CR3","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","volume":"10","author":"TO Nielsen","year":"2004","unstructured":"Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367\u20135374","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"2092_CR4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1634\/theoncologist.2011-S1-61","volume":"16","author":"CM Perou","year":"2011","unstructured":"Perou CM (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16(Suppl 1):61\u201370","journal-title":"Oncologist"},{"issue":"15 Pt 1","key":"2092_CR5","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2092_CR6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721\u20131728","journal-title":"Cancer"},{"key":"2092_CR7","first-page":"175","volume":"5","author":"CA Minami","year":"2011","unstructured":"Minami CA, Chung DU, Chang HR (2011) Management options in triple-negative breast cancer. Breast Cancer (Auckl) 5:175\u2013199","journal-title":"Breast Cancer (Auckl)"},{"issue":"1","key":"2092_CR8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118\u2013145","journal-title":"J Clin Oncol"},{"issue":"2","key":"2092_CR9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","volume":"12","author":"W Pao","year":"2011","unstructured":"Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12(2):175\u2013180","journal-title":"Lancet Oncol"},{"issue":"30","key":"2092_CR10","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1200\/JCO.2010.29.6038","volume":"28","author":"Y Sun","year":"2010","unstructured":"Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H (2010) Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28(30):4616\u20134620","journal-title":"J Clin Oncol"},{"issue":"1","key":"2092_CR11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1158\/1078-0432.CCR-05-0976","volume":"12","author":"JW Lee","year":"2006","unstructured":"Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH (2006) Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 12(1):57\u201361","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2092_CR12","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/bcr2857","volume":"13","author":"YH Teng","year":"2011","unstructured":"Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, Wong NS, Yip GW, Bay BH, Tan PH (2011) Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res 13(2):R35","journal-title":"Breast Cancer Res"},{"issue":"8","key":"2092_CR13","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/modpathol.3800438","volume":"18","author":"R Bhargava","year":"2005","unstructured":"Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B (2005) EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18(8):1027\u20131033","journal-title":"Mod Pathol"},{"issue":"1","key":"2092_CR14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PPO.0b013e3181d24fc1","volume":"16","author":"ML Burness","year":"2010","unstructured":"Burness ML, Grushko TA, Olopade OI (2010) Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J 16(1):23\u201332","journal-title":"Cancer J"},{"issue":"2","key":"2092_CR15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cancergencyto.2010.07.118","volume":"203","author":"B Gumuskaya","year":"2010","unstructured":"Gumuskaya B, Alper M, Hucumenoglu S, Altundag K, Uner A, Guler G (2010) EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet Cytogenet 203(2):222\u2013229","journal-title":"Cancer Genet Cytogenet"},{"issue":"5","key":"2092_CR16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/labinvest.3700077","volume":"84","author":"C Kersting","year":"2004","unstructured":"Kersting C, Tidow N, Schmidt H, Liedtke C, Neumann J, Boecker W, van Diest PJ, Brandt B, Buerger H (2004) Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 84(5):582\u2013587","journal-title":"Lab Invest"},{"issue":"9","key":"2092_CR17","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/sj.bjc.6604341","volume":"98","author":"Y Fukuyoshi","year":"2008","unstructured":"Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M (2008) EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer 98(9):1536\u20131539","journal-title":"Br J Cancer"},{"issue":"9","key":"2092_CR18","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1158\/1541-7786.MCR-08-0522","volume":"7","author":"E Lin","year":"2009","unstructured":"Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z (2009) Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7(9):1466\u20131476","journal-title":"Mol Cancer Res"},{"issue":"7","key":"2092_CR19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm2438","volume":"9","author":"AE Karnoub","year":"2008","unstructured":"Karnoub AE, Weinberg RA (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9(7):517\u2013531","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6892","key":"2092_CR20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949\u2013954","journal-title":"Nature"},{"issue":"5","key":"2092_CR21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10637-009-9279-8","volume":"28","author":"R Gollamudi","year":"2010","unstructured":"Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM, Mani S, Goel S (2010) Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 28(5):641\u2013649. doi: 10.1007\/s10637-009-9279-8","journal-title":"Invest New Drugs"},{"issue":"7308","key":"2092_CR22","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nature09208","volume":"466","author":"Z Kan","year":"2010","unstructured":"Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466(7308):869\u2013873. doi: 10.1038\/nature09208","journal-title":"Nature"},{"issue":"7","key":"2092_CR23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","volume":"4","author":"J Kononen","year":"1998","unstructured":"Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844\u2013847","journal-title":"Nat Med"},{"issue":"5","key":"2092_CR24","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-07-1658","volume":"14","author":"MC Cheang","year":"2008","unstructured":"Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368\u20131376","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2092_CR25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129\u20132139","journal-title":"N Engl J Med"},{"issue":"11","key":"2092_CR26","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/modpathol.2008.104","volume":"21","author":"T Schlomm","year":"2008","unstructured":"Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 21(11):1371\u20131378","journal-title":"Mod Pathol"},{"issue":"20","key":"2092_CR27","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","volume":"21","author":"FR Hirsch","year":"2003","unstructured":"Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21(20):3798\u20133807","journal-title":"J Clin Oncol"},{"issue":"11","key":"2092_CR28","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jcp.2009.066548","volume":"62","author":"M Varella-Garcia","year":"2009","unstructured":"Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, Nagelmeier I, Ruschoff J, Schmitt M, Arbogast S, Cappuzzo F (2009) EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 62(11):970\u2013977","journal-title":"J Clin Pathol"},{"key":"2092_CR29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10549-011-1518-y","volume":"132","author":"S Boyault","year":"2012","unstructured":"Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, Tabone E, Puisieux A, Wang Q (2012) Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat 132:29\u201339","journal-title":"Breast Cancer Res Treat"},{"key":"2092_CR30","first-page":"S307","volume":"4","author":"JL Greve De","year":"2009","unstructured":"De Greve JL, Teugels E, De Mey J, Geers C, Galdermans D, Decoster L, In\u2032t Veld P, Schallier D, Taton M, Shahidi M (2009) Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu. J Thorac Oncol 4:S307 (abstr.)","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2092_CR31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2006.05.023","volume":"10","author":"SE Wang","year":"2006","unstructured":"Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10(1):25\u201338","journal-title":"Cancer Cell"},{"issue":"9","key":"2092_CR32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","volume":"97","author":"F Cappuzzo","year":"2005","unstructured":"Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9):643\u2013655","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"2092_CR33","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2007.14.0111","volume":"26","author":"FR Hirsch","year":"2008","unstructured":"Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA Jr, Varella-Garcia M, Gandara DR (2008) Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26(20):3351\u20133357","journal-title":"J Clin Oncol"},{"issue":"2","key":"2092_CR34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa050736","volume":"353","author":"MS Tsao","year":"2005","unstructured":"Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA (2005) Erlotinib in lung cancer\u2014molecular and clinical predictors of outcome. N Engl J Med 353(2):133\u2013144","journal-title":"N Engl J Med"},{"issue":"6","key":"2092_CR35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrclinonc.2009.62","volume":"6","author":"H Linardou","year":"2009","unstructured":"Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S (2009) Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 6(6):352\u2013366","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2092_CR36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ijc.20591","volume":"113","author":"JW Lee","year":"2005","unstructured":"Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH (2005) Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer 113(3):510\u2013511","journal-title":"Int J Cancer"},{"issue":"10","key":"2092_CR37","first-page":"4219","volume":"30","author":"H Uramoto","year":"2010","unstructured":"Uramoto H, Shimokawa H, Nagata Y, Ono K, Hanagiri T (2010) EGFR-activating mutations are not present in breast tumors of Japanese patients. Anticancer Res 30(10):4219\u20134222","journal-title":"Anticancer Res"},{"key":"2092_CR38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1471-2407-10-136","volume":"10","author":"A Sanchez-Munoz","year":"2010","unstructured":"Sanchez-Munoz A, Gallego E, de Luque V, Perez-Rivas LG, Vicioso L, Ribelles N, Lozano J, Alba E (2010) Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer 10:136","journal-title":"BMC Cancer"},{"issue":"1","key":"2092_CR39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10549-008-0295-8","volume":"118","author":"S Nofech-Mozes","year":"2009","unstructured":"Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, Hanna WM (2009) Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat 118(1):131\u2013137","journal-title":"Breast Cancer Res Treat"},{"key":"2092_CR40","first-page":"9","volume-title":"Pathology and genetics of tumours of the breast and female genital organs. World Health Organisation classification of tumours","author":"WHO","year":"2003","unstructured":"WHO (2003) Tumors of the breast. In: Tavassoli FA, Devilee P (eds) Pathology and genetics of tumours of the breast and female genital organs. World Health Organisation classification of tumours. IARC Press, Lyon, pp 9\u2013112"},{"issue":"5","key":"2092_CR41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403\u2013410","journal-title":"Histopathology"},{"key":"2092_CR42","volume-title":"International Union against cancer (UICC) TNM classification of malignant tumours","author":"LH Sobin","year":"2010","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C (2010) International Union against cancer (UICC) TNM classification of malignant tumours, 7th edn. Wiley-Liss, New York","edition":"7"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2092-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2092-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2092-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:34:02Z","timestamp":1559234042000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2092-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,19]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["2092"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2092-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,19]]}}}